Delivering affordable cancer care in high-income countries (Q56994721)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Delivering affordable cancer care in high-income countries (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Eitan Amir

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Peter Boyle

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Philippe Autier

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Silvia Camporesi

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Peter Naredi

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Murray Brennan

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Dirk Verellen

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Rodney J. Hicks

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

Alexander M. M. Eggermont

13 February 2020

18

object named as

Alexander Eggermont

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

10

Ian F Tannock

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

11

Tito Fojo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

25

Guy Storme

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

4

John Zalcberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Jeffrey Peppercorn

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Karol Sikora

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Neal J Meropol

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

David Khayat

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jim Siderov

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Steve Williamson

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

J Gordon McVie

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Arnie D Purushotham

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Michael L Steinberg

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Mark De Ridder

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Susan A McCloskey

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Terence Roberts

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Peter J Ell

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Bradford R Hirsch

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

David P Carbone

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Kevin A Schulman

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Paul Catchpole

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

David Taylor

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jan Geissler

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Nancy G Brinker

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

David Meltzer

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

David Kerr

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Matti Aapro

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

0 references

publication date

1 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

933-980

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cost of cancer care: issues and implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

The price of innovation: new estimates of drug development costs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Comparison of approaches for estimating incidence costs of care for colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Projections of the cost of cancer care in the United States: 2010-2020.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cancer's next frontier: addressing high and increasing costs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Evaluation of trends in the cost of initial cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Patient-Centered Outcomes Research Institute: the intersection of science and health care

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Expansion of cancer care and control in countries of low and middle income: a call to action

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Concerns about Provenge simmer as CMS ponders coverage

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Listening to Provenge--what a costly cancer treatment says about future Medicare policy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Physicians' views on defensive medicine: a national survey

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Commentary: health care technology and medical education: putting physical diagnosis in its proper place

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Practice patterns and guideline adherence of medical oncologists in managing patients with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

National costs of the medical liability system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

The impact of state laws limiting malpractice damage awards on health care expenditures

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Defensive medicine among high-risk specialist physicians in a volatile malpractice environment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Health care costs in the last week of life: associations with end-of-life conversations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Equipoise lost: ethics, costs, and the regulation of cancer clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Future supply and demand for oncologists : challenges to assuring access to oncology services

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Value and cancer care: toward an equitable future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

What is the value of oncology medicines?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Effects of cost sharing on care seeking and health status: results from the Medical Outcomes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

American Society of Clinical Oncology guidance statement: the cost of cancer care

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Reforming health care reform in the 112th Congress

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

The burden of illness of cancer: economic cost and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Generalisability in economic evaluation studies in healthcare: a review and case studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Making cost assessments based on RCTs more useful to decision-makers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Emerging lessons from the drug effectiveness review project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

European perspective on the costs and cost-effectiveness of cancer therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Development of WHO guidelines on generalized cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Criteria for deciding cost-effectiveness for expensive new anti-cancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Advances in cancer therapeutics and patient access to new drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

A rational framework for decision making by the National Institute For Clinical Excellence (NICE).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Helping poorer countries make locally informed health decisions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Information on cost-effectiveness: an essential product of a national comparative effectiveness program

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Evolution of the randomized controlled trial in oncology over three decades

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

The impact of the 'Clinical Trials' directive on the cost and conduct of non-commercial cancer trials in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

10 years of NICE: still growing and still controversial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

National Institute for Clinical Excellence and its value judgments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

NICE system...shame about the side-effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

NICE and the challenge of cancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Patient access schemes for high-cost cancer medicines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Going off-label without venturing off-course: evidence and ethical off-label prescribing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Off-label use of anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Oncologists judge themselves the best judges of cancer treatments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

The impact of insurance on access to cancer clinical trials at a comprehensive cancer center

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Fighting against age discrimination in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Need for global action for cancer control

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

New Technology and Health Care Costs — The Case of Robot-Assisted Surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Comparative effectiveness of minimally invasive vs open radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Robot-assisted radical cystectomy versus open radical cystectomy: a complete cost analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cost of care for elderly cancer patients in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Breast cancer in elderly women. Optimizing the treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

A Review of the Clinical Evidence for Intensity-modulated Radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Imaging in radiation oncology: a perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Innovations in image-guided radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Stereotactic body radiation therapy in multiple organ sites

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Proton radiation in the management of localized cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Degradation of the Bragg peak due to inhomogeneities.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Proton beam therapy and the convoluted pathway to incorporating emerging technology into routine medical care in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

21 years of biologically effective dose

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Bystander effects and their implications for clinical radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Macrophages enhance the radiosensitizing activity of lipid A: a novel role for immune cells in tumor cell radioresponse.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

A sense of danger from radiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Stereotactic body radiation therapy for inoperable early stage lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Evidence that consumers are skeptical about evidence-based health care

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Patient time costs associated with cancer care

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

A strategy for health care reform--toward a value-based system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

De Testimonio: on the evidence for decisions about the use of therapeutic interventions.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Implications of comparative effectiveness research for radiation oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Coverage options for promising technologies: Medicare's 'coverage with evidence development'

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Bayesian propensity score analysis for observational data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

A method for the detailed assessment of the appropriateness of medical technologies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Assessing the appropriateness of care--its time has come

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

The overthrow of the (evidence) hierarchy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Clinical role of positron emission tomography in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

PET/MRI: a different spin from under the rim.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

How can we tell if PET imaging for cancer is cost effective?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

The uncritical use of high-tech medical imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Translating cancer research into targeted therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Joint project of the International Network of Agencies for Health Technology Assessment--Part 2: Managing the diffusion of positron emission tomography with health technology assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cost-effectiveness of PET imaging in clinical oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Health technology assessment of PET in oncology: re Eur J Nucl Med Mol Imaging 2003; 30:637-641

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Comparative effectiveness research: what it means for radiology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Costs of health care: a lopsided debate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Are health economics making us sick?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Late-stage cancer detection in the USA is costing lives

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Translational research: Crossing the valley of death

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Nuclear medicine and thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Applications of positron emission tomography in the development of molecular targeted cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

The risk of exaggerated risk aversion-a life and death struggle for molecular imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

We have met the enemy and he is us!

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Health technology assessment and cancer imaging: who should be setting the agenda?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Initial sequencing and analysis of the human genome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Genomics and the continuum of cancer care

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

From bedside to bench to bedside to clinical practice: an odyssey with irinotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Letting the genome out of the bottle--will we get our wish?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Replication validity of genetic association studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Growing calls in United States, Europe to improve regulation of genetic testing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

The Path to Personalized Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cost effectiveness of pharmacogenomics: a critical and systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

A review of economic evaluations of genetic testing services and interventions (2004-2009).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Economic analyses of human genetics services: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

A policy approach to the development of molecular diagnostic tests

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Economic implications of potential changes to regulatory and reimbursement policies for medical devices

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Access with evidence development: the US experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Where's the value in health care?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Deconstructing the drug development process: the new face of innovation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Discounting the value of life

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Despite steep costs, payments for new cancer drugs make economic sense

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cancer treatment cost in the United States: has the burden shifted over time?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Assessing the economic challenges posed by orphan drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Estimates of the cancer incidence and mortality in Europe in 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Cancer risk diversity in non-western migrants to Europe: An overview of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Trends in underinsurance and the affordability of employer coverage, 2004-2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Out-of-pocket health-care expenditures among older Americans with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Medical Bankruptcy in the United States, 2007: Results of a National Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Early accelerated approval for highly targeted cancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Designing transparency systems for medical care prices

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Introduction: The prevention agenda

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Integrating care through bundled payments--lessons from The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Why do we love medicines so much? An evolutionary perspective on the human love of pills, potions and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970141-3

7 January 2021

Primary extraosseous Ewing sarcoma of the lung in children

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.3332/ECANCER.2013.312

Identifiers

DOI

10.1016/S1470-2045(11)70141-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21958503%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference